Explore our latest white paper on the evolving landscape of immunotherapy in oncology, where we discuss the significant advancements and regulatory approvals shaping new therapeutic paradigms. Key points include the expanded use of immune checkpoint inhibitors (ICIs) such as toripalimab and tremelimumab, which have become frontline treatments for various cancers. We also highlight the remarkable progress in other immunotherapy modalities, including CAR-T and TCR-T cell therapies, personalized cancer vaccines driven by mRNA technologies, and multi-specific antibodies. Additionally, the paper covers the global approval of oncolytic viral (OV) therapies, which selectively target and kill cancer cells. We address the impact and challenges of immunotherapy, including resistance to treatments and immune-related adverse events, and discuss the potential for new clinical trial strategies to further revolutionize cancer care.

Stay informed about ongoing oncology clinical trials and promising advancements, shaping the future of oncological care.

Download our white paper to discover:

1. Regulatory approvals of immuno-oncology therapies
2. The landscape of immune checkpoint inhibitors (ICIs)
3. Advances in other immunotherapy modalities
4. Approved oncolytic viral (OV) therapies
5. Impact, challenges, and future directions of immunotherapy

Learn more about our related services and resources:

TFS Oncology